FDA investigates risk of secondary lymphomas after CAR-T immunotherapy
- PMID: 38071995
- DOI: 10.1016/S1470-2045(23)00631-9
FDA investigates risk of secondary lymphomas after CAR-T immunotherapy
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
